GW Pharma (GWPH) Received its Third Buy in a Row


After Guggenheim and Cantor Fitzgerald gave GW Pharma (NASDAQ: GWPH) a Buy rating last month, the company received another Buy, this time from Cowen & Co. Analyst Phil Nadeau maintained a Buy rating on GW Pharma yesterday and set a price target of $175. The company’s shares closed yesterday at $170.97, close to its 52-week high of $182.23.

According to TipRanks.com, Nadeau is a 5-star analyst with an average return of 8.3% and a 49.3% success rate. Nadeau covers the Healthcare sector, focusing on stocks such as Rocket Pharmaceuticals Inc, Rhythm Pharmaceuticals Inc, and Allogene Therapeutics Inc.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for GW Pharma with a $178.43 average price target, a 4.4% upside from current levels. In a report issued on February 27, Cantor Fitzgerald also reiterated a Buy rating on the stock with a $193 price target.

See today’s analyst top recommended stocks >>

Based on GW Pharma’s latest earnings release for the quarter ending December 31, the company reported a quarterly GAAP net loss of $71.31 million. In comparison, last year the company had a GAAP net loss of $62.29 million.

Based on the recent corporate insider activity of 14 insiders, corporate insider sentiment is negative on the stock.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

GW Pharmaceuticals Plc is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel therapeutics. It offers its lead cannabinoid product, Epidiolex oral solution CV, a pharmaceutical formulation of cannabidiol (CBD) focusing on the treatment of seizures associated with tuberous sclerosis complex.

Read More on GWPH:

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts